Work

Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning

Year: 2025

Type: article

Abstract: Topical clascoterone (TC) is the first topical antiandrogen approved by the Food and Drug Administration (FDA) for the treatment of acne and recently approved in Europe. Through bibliographic searches in Medline and Google Scholar, we conducted a narrative review to assess the usefulness of TC in acne management. Several randomized clinical trials have demonstrated its efficacy and safety (with virtually no systemic adverse effects), but few have compared its effectiveness with other topical agents or its use in combination. It is a highly interesting therapeutic alternative, particularly for patients who do not tolerate other topical treatments or in cases of acne with a strong hormonal component. U.S. treatment guidelines conditionally recommend it for acne management due to its high cost. The strength of recommendation is lower than that of topical retinoids and benzoyl peroxide.

Source: Actas Dermo-Sifiliográficas

DOI: 10.1016/j.ad.2025.104587

Authors: P. Balado-Simó, M. Brufau-Cochs, D. Morgado-Carrasco

Institutions: Hospital Clínic de Barcelona, Universitat de Barcelona, Fundació Salut Empordà, Hospital de Figueres

Language: English

Topic: Acne and Rosacea Treatments and Effects

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,080